Impaired metabolic brain networks associated with neurotransmission systems in the α-synuclein spectrum.

[en] INTRODUCTION: While the involvement of multiple neurotransmitter systems in α-synucleinopathies is reported, a comprehensive study on their metabolic connectivity reconfiguration in the preclinical and clinical disease-spectrum is lacking. We aimed to investigate shared and disease-specific neural vulnerabilities of the nigro-striato-cortical dopaminergic, noradrenergic and cholinergic networks within the α-synuclein-spectrum, by means of metabolic connectivity approach. METHODS: We collected 34 polysomnography-confirmed isolated REM sleep behaviour disorder (iRBD) subjects, 29 idiopathic Parkinson's disease (PD) patients without dementia, 30 patients with probable dementia with Lewy bodies (DLB), and 50 healthy controls for comparisons. Neurotransmission networks' analyses were performed through multivariate partial correlations based on FDG-PET brain metabolic data. RESULTS: We found: a) the nigro-striato-cortical dopaminergic network with a limited reconfiguration in individuals with iRBD, but moderate-to-severe alterations in patients with DLB and PD; b) an extended connectivity alteration of the noradrenergic network in all groups; c) changes within the cholinergic networks connectivity in the whole disease-spectrum, with some differences: PD with only moderate connectivity reconfiguration and DLB with the most severe alterations, some of these shared with iRBD. CONCLUSIONS: Synucleinopathies can be considered multisystem disorders, with common and disease-specific neurotransmission networks reconfigurations. The present findings indicate dopaminergic connectivity alterations only when associated with parkinsonism, a very early involvement of noradrenergic networks, occurring in both the iRBD and in symptomatic PD/DLB patients and cholinergic alterations with disease-specific vulnerabilities shared by iRBD and DLB. The latter finding may represent an early biomarker of disease progression to dementia.

Disciplines :

Radiology, nuclear medicine & imaging

Author, co-author :

Carli, Giulia

Caminiti, Silvia Paola

Sala, Arianna ; UniSR

Galbiati, Andrea

Pilotto, Andrea

Ferini-Strambi, Luigi

Padovani, Alessandro

Perani, Daniela

Language :

English

Title :

Impaired metabolic brain networks associated with neurotransmission systems in the α-synuclein spectrum.

Publication date :

2020

Journal title :

Parkinsonism & related disorders

ISSN :

1353-8020

eISSN :

1873-5126

Volume :

Pages :

113-122

Peer reviewed :

Peer reviewed

Commentary :

Available on ORBi :

since 02 June 2021

Statistics

Number of views

46 (2 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Goedert, M., Jakes, R., Spillantini, M.G., The synucleinopathies: twenty years on. J. Parkinsons Dis. 7 (2017), S51–S69.
Uchihara, T., Giasson, B.I., Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 131 (2016), 49–73.
Gaugler, M.N., Genc, O., Bobela, W., Mohanna, S., Ardah, M.T., El-Agnaf, O.M., Cantoni, M., Bensadoun, J.-C., Schneggenburger, R., Knott, G.W., Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 123 (2012), 653–669.
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., Del Tredici, K., Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318 (2004), 121–134.
Hall, H., Reyes, S., Landeck, N., Bye, C., Leanza, G., Double, K., Thompson, L., Halliday, G., Kirik, D., Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain 137 (2014), 2493–2508.
Stokholm, M.G., Iranzo, A., Østergaard, K., Serradell, M., Otto, M., Svendsen, K.B., Garrido, A., Vilas, D., Fedorova, T.D., Santamaria, J., Cholinergic denervation in idiopathic rapid eye movement sleep behaviour disorder patients. Eur. J. Neurol. 27:4 (2019), 644–652.
Knudsen, K., Fedorova, T.D., Hansen, A.K., Sommerauer, M., Otto, M., Svendsen, K.B., Nahimi, A., Stokholm, M.G., Pavese, N., Beier, C.P., In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17:7 (2018), 618–628.
Ferini-Strambi, L., Fasiello, E., Sforza, M., Salsone, M., Galbiati, A., Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder. Expert Rev. Neurother. 19 (2019), 1069–1087.
St Louis, E.K., Boeve, A.R., Boeve, B.F., REM S leep B ehavior D isorder in P arkinson's D isease and O ther S ynucleinopathies. Mov. Disord. 32 (2017), 645–658.
Högl, B., Stefani, A., Videnovic, A., Idiopathic REM sleep behaviour disorder and neurodegeneration—an update. Nat. Rev. Neurol., 14, 2018, 40.
Galbiati, A., Verga, L., Giora, E., Zucconi, M., Ferini-Strambi, L., The risk of neurodegeneration in REM Sleep Behavior Disorder: a systematic review and meta-analysis of longitudinal studies. Sleep Med. Rev. 43 (2018), 37–46.
Boeve, B.F., Silber, M.H., Ferman, T.J., Lin, S.C., Benarroch, E.E., Schmeichel, A.M., Ahlskog, J.E., Caselli, R.J., Jacobson, S., Sabbagh, M., Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 14 (2013), 754–762.
Iranzo, A., Tolosa, E., Gelpi, E., Molinuevo, J.L., Valldeoriola, F., Serradell, M., Sanchez-valle, R., Vilaseca, I., Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 12 (2013), 443–453, 10.1016/S1474-4422(13)70056-5.
Boeve, B.F., Dickson, D.W., Olson, E.J., Shepard, J.W., Silber, M.H., Ferman, T.J., Ahlskog, J.E., Benarroch, E.E., Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med. 8 (2007), 60–64.
Uchiyama, M., Isse, K., Tanaka, K., Yokota, N., Hamamoto, M., Aida, S., Ito, Y., Yoshimura, M., Okawa, M., Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 45 (1995), 709–712.
Vilas, D., Iranzo, A., Tolosa, E., Aldecoa, I., Berenguer, J., Vilaseca, I., Martí, C., Serradell, M., Lomeña, F., Alós, L., Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 15 (2016), 708–718.
Sprenger, F.S., Stefanova, N., Gelpi, E., Seppi, K., Navarro-Otano, J., Offner, F., Vilas, D., Valldeoriola, F., Pont-Sunyer, C., Aldecoa, I., Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology 85 (2015), 1761–1768.
Caminiti, S., Tettamanti, M., Sala, A., Presotto, L., Iannaccone, S., Cappa, S.F., Magnani, G., Perani, D., Metabolic connectomics targeting brain pathology in dementia with Lewy bodies. J. Cerebr. Blood Flow Metabol. 37 (2017), 1311–1325, 10.1177/0271678X16654497.
Sala, Caminiti, S.P., Presotto, L., Premi, E., Pilotto, A., Turrone, R., Cosseddu, M., Alberici, A., Paghera, B., Borroni, B., Padovani, A., Perani, D., Altered brain metabolic connectivity at multiscale level in early Parkinson ’ s disease. Sci. Rep., 7, 2017, 4256, 10.1038/s41598-017-04102-z.
Caminiti, S.P., Presotto, L., Baroncini, D., Garibotto, V., Moresco, R.M., Gianolli, L., Volonté, M.A., Antonini, A., Perani, D., Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. NeuroImage Clin 14 (2017), 734–740.
Meles, S.K., Vadasz, D., Renken, R.J., Sittig-Wiegand, E., Mayer, G., Depboylu, C., Reetz, K., Overeem, S., Pijpers, A., Reesink, F.E., FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder. Mov. Disord. 32 (2017), 1482–1486.
Teune, L.K., Renken, R.J., de Jong, B.M., Willemsen, A.T., van Osch, M.J., Roerdink, J.B.T.M., Dierckx, R.A., Leenders, K.L., Parkinson's disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. NeuroImage Clin 5 (2014), 240–244.
Kogan R.V., Janzen A., Meles S.K., Sittig E., Renken R.J., Gurvits V., Mayer G., Leenders K.L., Oertel W.H., Group R.W., Four-year follow-up of [18F] fluorodeoxyglucose positron emission tomography–based Parkinson's disease–related pattern expression in 20 patients with isolated rapid eye movement sleep behavior disorder shows prodromal progression, Mov. Disord. (n.d.), doi:10.1002/mds.28260.
Sala, A., Perani, D., Brain molecular connectivity in neurodegenerative diseases: recent advances and new perspectives using Positron Emission Tomography. Front. Neurosci., 13, 2019, 617.
Pievani, M., Filippini, N., van den Heuvel, M.P., Cappa, S.F., Frisoni, G.B., Brain connectivity in neurodegenerative diseases-from phenotype to proteinopathy. Nat. Rev. Neurol. 10 (2014), 620–633, 10.1038/nrneurol.2014.178.
Fornito, A., Zalesky, A., Breakspear, M., The connectomics of brain disorders. Nat. Publ. Gr. 16 (2015), 159–172, 10.1038/nrn3901.
Yakushev, I., Drzezga, A., Habeck, C., Metabolic connectivity: methods and applications. Curr. Opin. Neurol. 30 (2017), 677–685.
Horwitz, B., Duara, R., Rapoport, S.I., Intercorrelations of glucosemetabolic rates between brain regions: application to healthy males in a state of reduced sensory input. J. Cerebr. Blood Flow Metabol. 4 (1984), 484–499, 10.1038/jcbfm.1984.73.
Veronese, M., Moro, L., Arcolin, M., Dipasquale, O., Rizzo, G., Expert, P., Khan, W., Fisher, P.M., Svarer, C., Bertoldo, A., Covariance statistics and network analysis of brain PET imaging studies. Sci. Rep. 9 (2019), 1–15.
Bennett, C.M., Wolford, G.L., Miller, M.B., The principled control of false positives in neuroimaging. Soc. Cognit. Affect Neurosci. 4 (2009), 417–422.
Myers, L., Sirois, M.J., S pearman correlation coefficients, differences between. Encycl. Stat. Sci., 2004, 10.1002/0471667196.ess5050.pub2.
Goswami, S., Murthy, C.A., Das, A.K., Sparsity measure of a network graph: Gini index. Inf. Sci. 462 (2018), 16–39.
Gini, C., Variabilità e mutabilità (Variability and Mutability), Tipogr. Di Paolo Cuppini. Bol. Italy., 1912, 156.
Mencarelli, L., Biagi, M.C., Salvador, R., Romanella, S., Ruffini, G., Rossi, S., Santarnecchi, E., Network mapping of connectivity alterations in disorder of consciousness: towards targeted neuromodulation. J. Clin. Med., 9, 2020, 828.
Dice, L.R., Measures of the amount of ecologic association between species. Ecology 26 (1945), 297–302.
Massa, F., Arnaldi, D., De Cesari, F., Girtler, N., Brugnolo, A., Grazzini, M., Bauckneht, M., Meli, R., Morbelli, S., Pardini, M., Neuroimaging findings and clinical trajectories of Lewy body disease in patients with MCI. Neurobiol. Aging 76 (2019), 9–17.
Huber, M., Beyer, L., Prix, C., Schönecker, S., Palleis, C., Rauchmann, B., Morbelli, S., Chincarini, A., Bruffaerts, R., Vandenberghe, R., Metabolic correlates of dopaminergic loss in dementia with lewy bodies. Mov. Disord. 35 (2020), 595–605.
Niethammer, M., Tang, C.C., Ma, Y., Mattis, P.J., Ko, J.H., Dhawan, V., Eidelberg, D., Parkinson's disease cognitive network correlates with caudate dopamine. Neuroimage 78 (2013), 204–209.
Schindlbeck, K.A., Eidelberg, D., Network imaging biomarkers: insights and clinical applications in Parkinson's disease. Lancet Neurol. 17 (2018), 629–640.
Verger, A., Horowitz, T., Chawki, M.B., Eusebio, A., Bordonne, M., Azulay, J.-P., Girard, N., Guedj, E., From metabolic connectivity to molecular connectivity: application to dopaminergic pathways. Eur. J. Nucl. Med. Mol. Imag. 47:2 (2019), 413–424, 10.1007/s00259-019-04574-3.
Parkkinen, L., Pirttilä, T., Alafuzoff, I., Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol. 115 (2008), 399–407, 10.1007/s00401-008-0346-6.
Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A.E., MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30 (2015), 1591–1601.
Walker, Z., Costa, D.C., Walker, R.W.H., Lee, L., Livingston, G., Jaros, E., Perry, R., McKeith, I., Katona, C.L.E., Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62 (2004), 1568–1572.
Luppi, P., Clément, O., Garcia, S.V., Brischoux, F., Fort, P., New aspects in the pathophysiology of rapid eye movement sleep behavior disorder: the potential role of glutamate, gamma-aminobutyric acid, and glycine. 14, 714-718 https://doi.org/10.1016/j.sleep.2013.02.004, 2013.
Pfeiffer, R.F., Non-motor symptoms in Parkinson's disease. Park. Relat. Disord. 22 (2016), S119–S122, 10.1016/j.parkreldis.2015.09.004.
Nahimi, A., Kinnerup, M.B., Sommerauer, M., Gjedde, A., Borghammer, P., Molecular imaging of the noradrenergic system in idiopathic Parkinson's disease. Int. Rev. Neurobiol., 2018, Elsevier, 251–274.
Vermeiren, Y., De Deyn, P.P., Targeting the norepinephrinergic system in Parkinson's disease and related disorders: the locus coeruleus story. Neurochem. Int. 102 (2017), 22–32.
Gratwicke, J., Jahanshahi, M., Foltynie, T., Parkinson's disease dementia: a neural networks perspective. Brain 138 (2015), 1454–1476.
Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73 (2009), 273–278.
Mesulam, M.-M., The cholinergic innervation of the human cerebral cortex. Prog. Brain Res. 145 (2004), 67–78.
Bohnen, N.I., Müller, M.L.T.M., Kotagal, V., Koeppe, R.A., Kilbourn, M.R., Gilman, S., Albin, R.L., Frey, K.A., Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J. Cerebr. Blood Flow Metabol. 32 (2012), 1609–1617.
Mazère, J., Lamare, F., Allard, M., Fernandez, P., Mayo, W., 123I-Iodobenzovesamicol SPECT imaging of cholinergic systems in dementia with Lewy bodies. J. Nucl. Med. 58 (2017), 123–128, 10.2967/jnumed.116.176180.
Delli Pizzi, S., Franciotti, R., Taylor, J.-P., Thomas, A., Tartaro, A., Onofrj, M., Bonanni, L., Thalamic involvement in fluctuating cognition in dementia with Lewy bodies: magnetic resonance evidences. Cerebr. Cortex 25 (2015), 3682–3689.
Carli, G., Caminiti, S.P., Galbiati, A., Marelli, S., Casoni, F., Padovani, A., Ferini-Strambi, L., Perani, D., In vivo signatures of neurodegeneration in isolated rapid eye movement behaviour disorder. Eurpean J. Neurol., 2020, 10.1111/ene.14215 ISO 690.
Boeve, B.F., Schenck, C.H., Högl, B., Videnovic, A., (eds.) REM Sleep Behavior Disorder Associated with Dementia with Lewy Bodies BT - Rapid-Eye-Movement Sleep Behavior Disorder, 2019, Springer International Publishing, Cham, 67–76, 10.1007/978-3-319-90152-7_6.
Klein, J.C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., Baudrexel, S., Diederich, N.J., Heiss, W.-D., Hilker, R., Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74 (2010), 885–892.
Measso, G., Cavarzeran, F., Zappala, G., Lebowitz, B.D., Crook, T.H., Pirozzolo, F.J., Amaducci, L.A., Massari, D., Grigoletto, F., The mini-mental state examination: normative study of an Italian random sample. Dev. Neuropsychol. 9 (1993), 77–85.